Literature DB >> 23621510

Cyclization in opioid peptides.

Justyna Piekielna1, Renata Perlikowska, Katarzyna Gach, Anna Janecka.   

Abstract

Endogenous opioid peptides have been studied extensively as potential therapeutics for the treatment of pain. The major problems of using natural opioid peptides as drug candidates are their poor receptor specificity, metabolic instability and inability to reach the brain after systemic administration. A lot of synthetic efforts have been made to opioid analogs with improved pharmacological properties. One important structural modification leading to such analogs is cyclization of linear sequences. Intramolecular cyclization has been shown to improve biological properties of various bioactive peptides. Cyclization reduces conformational freedom responsible for the simultaneous activation of two or more receptors, increases metabolic stability and lipophilicity which may result in a longer half-life and easier penetration across biological membranes. This review deals with various strategies that have been employed to synthesize cyclic analogs of opioid peptides. Discussed are such bridging bonds as amide and amine linkages, sulfur-containing bonds, including monosulfide, disulfide and dithioether bridges, bismethylene bonds, monosulfide bridges of lanthionine and, finally, carbonyl and guanidine linkages. Opioid affinities and activities of cyclic analogs are given and compared with linear opioid peptides. Analgesic activities of analogs evaluated in the in vivo pain tests are also discussed.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23621510     DOI: 10.2174/1389450111314070008

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  9 in total

1.  Antinociceptive activity of thiazole-containing cyclized DAMGO and Leu-(Met) enkephalin analogs.

Authors:  Hannah M Harris; Shainnel O Eans; Michelle L Ganno; Jennifer C Davis; Colette T Dooley; Jay P McLaughlin; Adel Nefzi
Journal:  Org Biomol Chem       Date:  2019-05-16       Impact factor: 3.876

2.  Characterization of cyclic peptides containing disulfide bonds.

Authors:  Mindy Johnson; Mingtao Liu; Elaine Struble; Kanthi Hettiarachchi
Journal:  J Pharm Biomed Anal       Date:  2015-01-22       Impact factor: 3.935

3.  χ-Space Screening of Dermorphin-Based Tetrapeptides through Use of Constrained Arylazepinone and Quinolinone Scaffolds.

Authors:  Olivier Van der Poorten; Robin Van Den Hauwe; Emilie Eiselt; Cecilia Betti; Karel Guillemyn; Nga N Chung; François Hallé; Frédéric Bihel; Peter W Schiller; Dirk Tourwé; Philippe Sarret; Louis Gendron; Steven Ballet
Journal:  ACS Med Chem Lett       Date:  2017-10-04       Impact factor: 4.345

Review 4.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

Review 5.  Pharmacological Potential of the Endogenous Dipeptide Kyotorphin and Selected Derivatives.

Authors:  Juliana Perazzo; Miguel A R B Castanho; Sónia Sá Santos
Journal:  Front Pharmacol       Date:  2017-01-12       Impact factor: 5.810

6.  Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors.

Authors:  Karol Wtorek; Anna Adamska-Bartłomiejczyk; Justyna Piekielna-Ciesielska; Federica Ferrari; Chiara Ruzza; Alicja Kluczyk; Joanna Piasecka-Zelga; Girolamo Calo'; Anna Janecka
Journal:  Molecules       Date:  2019-12-05       Impact factor: 4.411

7.  Synthesis, Pharmacological Evaluation, and Computational Studies of Cyclic Opioid Peptidomimetics Containing β3-Lysine.

Authors:  Karol Wtorek; Piotr F J Lipiński; Anna Adamska-Bartłomiejczyk; Justyna Piekielna-Ciesielska; Jarosław Sukiennik; Alicja Kluczyk; Anna Janecka
Journal:  Molecules       Date:  2021-12-28       Impact factor: 4.411

Review 8.  Peptidomimetics and Their Applications for Opioid Peptide Drug Discovery.

Authors:  Yeon Sun Lee
Journal:  Biomolecules       Date:  2022-09-05

9.  In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist/NK1R Antagonist with Selective Cytotoxicity.

Authors:  Joanna Matalińska; Piotr F J Lipiński; Piotr Kosson; Katarzyna Kosińska; Aleksandra Misicka
Journal:  Int J Mol Sci       Date:  2020-10-19       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.